MedTrace Logo

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

NCT05799339 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2025-12-29

No results posted yet for this study

Summary

The goal of this study is to elicit information crucial for designing strategies to support engagement in cabotegravir, a long-acting injectable form of pre-exposure prophylaxis (PrEP) to reduce HIV risk among women who inject drugs (WWID), a population with high unmet need that has been understudied in all phases of PrEP research. The main questions this study aims to answer are:

1. How do WWID perceive long-acting injectable cabotegravir (CAB-LA) as a HIV prevention tool?
2. If and how their decisions to initiate CAB-LA as PrEP are informed by their experiences with other long-acting medications, experience with daily oral medications, and their personal circumstance (e.g., like housing or addition severity)?
3. Do PrEP outcomes (e.g., adherence) and engagement in care over time differ between WWID prescribed CAB-LA versus daily oral PrEP?

The sample for this study will be derived from and ongoing prospective trial of "TIARAS," a multi-component behavioral intervention designed to reduce HIV acquisition risk among women who inject drugs (see NCT05192434).

Conditions

  • HIV Infections
  • Opioid Use
  • Trauma, Psychological

Sponsors & Collaborators

Principal Investigators

  • Alexis M Roth, PhD, MPH · Drexel University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799339 on ClinicalTrials.gov